2026-525575-22-00RecruitingPhase 1
A first in human study of the safety, pharmacokinetics and pharmacodynamics of KLR-003 in healthy participants and patients with immune mediated diseases.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 23 Oct 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 182 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 7 May 2026
- Lead sponsor
- Klear Bio Inc.
- Diseases
- Psoriasis
- EU CT number
- 2026-525575-22-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 182
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Centre for Human Drug Research Coordinator of this site? Confirm its status | Leiden | Netherlands | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.